Widt-Levert LM, Tjan-Heijnen VCG, Bult P, et al. Stage migration in breast cancer: surgical decisions concerning isolated tumor cells and micro-metastases in the sentinel lymph node

Department of Surgery, University Medical Center, Nijmegen, The Netherlands.
European Journal of Surgical Oncology (Impact Factor: 3.01). 04/2003; 29(3):216-20. DOI: 10.1053/ejso.2002.1401
Source: PubMed


Sentinel lymph node biopsy has replaced the axillary lymph node dissection (ALND) in primary surgery for breast cancer in many hospitals and is expected to become the standard of care in due time. Since the sentinel lymph node is subjected to more extensive pathologic examination than the lymph nodes in the axillary dissection specimen, more patients are found to be node positive (N+); however many of them contain micro-metastases (<or=2mm). The consequence may be an overshoot of therapy: additional surgery for non-metastatic lymph nodes or systemic adjuvant therapy.
We examined 34 (out of a series of 38) clinically T1 (cT1) patients who had a SLN biopsy with or without ALND and compared them to a matched historical control group.
Twenty-one of 34 (62%) patients showed tumour cells in their SLN's. From these 21 patients in 13 (62%) the SLNs contained isolated tumour cells, of which 10 (77%) were detected only by immunohistochemistry (IHC), in four (19%) the SLNs contained micrometastases, and in four (19%) macrometastases. From 16 patients with isolated tumour cells or micrometastases in the SLN who underwent a regular ALND one had an H&E detected isolated tumour cell in a non-SLN and one patient with isolated tumour cells in the SLN who did not get a regular ALND developed an axillary recurrence 11 months after the primary treatment. On the other hand, three of four (75%) patients with macrometastases in the SLN had pathologically involved non-SLNs. In the majority (70%) of patients of the historical control group no lymph node involvement was seen. The percentage of macrometastases staged as lymph node positive in the control group was the same as in the studied group.
Most patients with cT1 breast cancer with isolated tumour cells or micrometastases in the SLN will not benefit from additional axillary dissection; 88% had a negative ALND. Since we cannot select the group that will benefit from ALND, this is still indicated in case of isolated tumour cells or micrometastases in the SLN. Since most of the affected SLNs show isolated tumour cells and are classified as pN0(i+), stage migration due to more meticulous pathologic examination does not occur according to the TNM classification. However some patients do not benefit from the introduction of the SLN, due to the high incidence of isolated tumour cells or micrometastases in the SLN. Many more patients than expected still end up with an ALND.

2 Reads

  • [Show abstract] [Hide abstract]
    ABSTRACT: ZusammenfassungBeim invasiven Mammakarzinom ist die axilläre Lymphonodektomie (ALN) der Level I und II mit der Entfernung von mindestens 10 Lymphknoten der operative Goldstandard. Die ALN dient als diagnostische Massnahme zur histopathologischen Tumorklassifikation, der Prognoseabschätzung, der lokoregionären Tumorkontrolle sowie zur adjuvanten Therapieentscheidung. Die Sentinellymphknoten-Entfernung (Sentinel-Node-Biopsie, SNB) stellt ein minimal-invasives Operationsverfahren dar, bei dem der Nodalstatus durch Entnahme von einem (oder mehreren) Wächterlymphknoten (Sentinellymphknoten) bestimmt werden kann. Die Methode setzt sich zunehmend in der klinischen Routine durch und ersetzt die konventionelle Axilladissektion bei Patientinnen mit frühem Mammakarzinom. Auf die klassische ALN sollte nur dann verzichtet werden, wenn in den Sentinellymphknoten sowohl in der Schnellschnitthistologie als auch in der endgültigen histopathologischen Untersuchung keine metastatische Infiltration nachgewiesen wird. Die Implementierung der SNB als operatives Standardverfahren sollte unter qualitätsgesicherten Bedingungen durchgeführt werden.
    Gynäkologisch-geburtshilfliche Rundschau 44(2):84-91. DOI:10.1159/000076861
  • [Show abstract] [Hide abstract]
    ABSTRACT: In 1992, Texas Instruments (TI) began executing the Ultra-Reliable Digital Avionics (URDA) contract sponsored by Wright Laboratory. Because of congressional action, the URDA program was suspended and is being restructured at the time of this writing. The purpose of the TI URDA program is to develop an advanced development module (ADM), which is a repackaging of two of TI's Aladdin basic processing modules (BPMs) into a SEM-E module format. This paper discusses the software-related aspects and proposed demonstration to be executed as part of the TI URDA program before program suspension/restructure
    Aerospace and Electronics Conference, 1994. NAECON 1994., Proceedings of the IEEE 1994 National; 06/1994
Show more

Similar Publications